# Meryx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meryx

- Industry: Biotechnology
- Headquarters: Chapel Hill, US
- Website: www.meryxpharma.com
- Total disclosed funding: $1.5M
- Latest round: Series A (Jan 1, 2015)
- Investors on record: 1

## About

Meryx Inc. is a pharmaceutical company focused on developing innovative products aimed at addressing unmet medical needs. Their work primarily involves creating prescription medications that provide solutions for chronic diseases.Founded in 2013, Meryx Inc., headquartered in Chapel Hill, US, specializes in pharmaceutical development. In December 2021, Tyrogenex Inc. acquired a majority stake from Eshelman Ventures. The investment target has completed 4 deals, with the most recent deal occurring on 2021-12-07 during a VENTURE DEBT round that raised USD 2.50 mn, contributing to a total of USD 1.50 mn raised since inception.Meryx Pharma specializes in developing innovative pharmaceutical products designed to address unmet medical needs across various therapeutic areas. The company's core offerings include prescription medications that target chronic diseases, ensuring improved patient outcomes through advanced formulations and delivery systems. These products are primarily marketed to healthcare providers, hospitals, and specialty pharmacies, focusing on enhancing the quality of life for patients suffering from conditions such as cardiovascular disorders and autoimmune diseases. Meryx Pharma has launched its key products in several international markets, including North America, Europe, and select regions in Asia, allowing them to cater to a diverse client base of healthcare professionals and patients seeking effective treatments.Meryx Pharma generates revenue through a combination of direct sales and partnerships with healthcare organizations. The company engages in business-to-business transactions, supplying its pharmaceutical products to hospitals and clinics while also establishing collaborations with wholesalers to expand distribution channels. Revenue is structured around product sales, with pricing models based on negotiated agreements with institutional clients and volume-based discounts for large orders. Flagship products contribute significantly to the firm's revenue stream, as they are in high demand within the healthcare market. The established partnerships enhance brand visibility and facilitate a more extensive reach into lucrative geographical markets.Meryx Inc. plans to utilize recent funding to accelerate the development of its clinical-stage and preclinical pipeline trials, following its acquisition by Tyrogenex Inc. The company is also focused on launching new products aimed at chronic disease management, with expectations for rollouts in the coming years. Expansion efforts are targeted toward new international markets, including additional regions in Asia and Europe, to diversify their market presence and reach more patients. The funding raised will support these initiatives, aiming for a robust growth trajectory in the pharmaceutical sector.

## Funding rounds

- Series A, Jan 1, 2015, $1.5M — Eshelman Ventures

## Investors

- Eshelman Ventures (https://capitalatlas.ai/funds/eshelman-ventures) — Series A